PARP1 inhibition elicits immune responses against non-small cell lung cancer.

Juncheng, Pan; Lafarge, Antoine; Kroemer, Guido; Castedo, Maria

Juncheng, Pan; Lafarge, Antoine; Kroemer, Guido; Castedo, Maria.

Afiliação

Juncheng P; Equipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Lafarge A; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Kroemer G; Faculté de médecine, Université de Paris Saclay, Kremlin Bicêtre, France.
Castedo M; Equipe 11 Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Paris, France.

Oncoimmunology ; 11(1): 2111915, 2022.

Article em En | MEDLINE | ID: mdl-35979387

RESUMO

High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Humanos; Imunidade; Neoplasias Pulmonares/tratamento farmacológico; Poli(ADP-Ribose) Polimerase-1; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Poli(ADP-Ribose) Polimerases/uso terapêutico

Palavras-chave

Anticancer immune response; immune escape; metabolism; non-small cell lung cancer; tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google